Bio-Techne (NASDAQ:TECH)‘s stock had its “buy” rating restated by research analysts at Leerink Swann in a note issued to investors on Tuesday.

Several other equities research analysts also recently weighed in on TECH. BidaskClub downgraded shares of Bio-Techne from a “buy” rating to a “hold” rating in a research report on Tuesday. Zacks Investment Research downgraded shares of Bio-Techne from a “buy” rating to a “hold” rating in a research report on Tuesday, August 15th. Deutsche Bank raised their price target on shares of Bio-Techne from $130.00 to $132.00 and gave the company a “buy” rating in a research report on Wednesday, August 9th. Finally, Citigroup reissued a “buy” rating and set a $115.00 price target (down previously from $125.00) on shares of Bio-Techne in a research report on Tuesday, October 24th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Bio-Techne has an average rating of “Buy” and an average price target of $134.33.

Shares of Bio-Techne (NASDAQ:TECH) traded down $3.38 during midday trading on Tuesday, hitting $129.81. 214,500 shares of the company’s stock were exchanged, compared to its average volume of 166,744. Bio-Techne has a fifty-two week low of $95.68 and a fifty-two week high of $136.39. The company has a market capitalization of $4,989.59, a P/E ratio of 38.38, a price-to-earnings-growth ratio of 3.32 and a beta of 0.75. The company has a quick ratio of 2.25, a current ratio of 2.87 and a debt-to-equity ratio of 0.35.

Bio-Techne (NASDAQ:TECH) last announced its earnings results on Tuesday, October 31st. The biotechnology company reported $0.90 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.82 by $0.08. Bio-Techne had a net margin of 12.54% and a return on equity of 14.11%. The business had revenue of $144.61 million during the quarter, compared to the consensus estimate of $142.37 million. During the same quarter last year, the firm earned $0.84 earnings per share. The business’s revenue for the quarter was up 10.7% on a year-over-year basis. research analysts forecast that Bio-Techne will post 3.76 earnings per share for the current year.

In related news, Director Robert V. Baumgartner sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $130.18, for a total transaction of $650,900.00. Following the completion of the sale, the director now owns 12,712 shares of the company’s stock, valued at $1,654,848.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Karen A. Holbrook sold 1,059 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $121.73, for a total transaction of $128,912.07. Following the sale, the director now directly owns 914 shares of the company’s stock, valued at approximately $111,261.22. The disclosure for this sale can be found here. Insiders have sold 6,259 shares of company stock valued at $804,102 in the last three months. 3.40% of the stock is owned by insiders.

Hedge funds have recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Bio-Techne by 12.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,456 shares of the biotechnology company’s stock worth $171,000 after purchasing an additional 163 shares during the last quarter. Zions Bancorporation purchased a new stake in Bio-Techne in the third quarter worth approximately $178,000. Flinton Capital Management LLC boosted its holdings in Bio-Techne by 84.8% in the second quarter. Flinton Capital Management LLC now owns 1,952 shares of the biotechnology company’s stock worth $229,000 after purchasing an additional 896 shares during the last quarter. Turner Investments LLC purchased a new stake in Bio-Techne in the third quarter worth approximately $242,000. Finally, Koch Industries Inc. purchased a new stake in Bio-Techne in the second quarter worth approximately $286,000. Institutional investors own 97.03% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.americanbankingnews.com/2017/12/05/bio-technes-tech-buy-rating-reaffirmed-at-leerink-swann.html.

Bio-Techne Company Profile

Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.

Analyst Recommendations for Bio-Techne (NASDAQ:TECH)

Receive News & Ratings for Bio-Techne Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne Corp and related companies with MarketBeat.com's FREE daily email newsletter.